Merck KGaA (MRK) PT Set at €116.00 by Berenberg Bank
Merck KGaA (FRA:MRK) has been given a €116.00 ($134.88) target price by stock analysts at Berenberg Bank in a report issued on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Berenberg Bank’s target price points to a potential upside of 29.19% from the stock’s current price.
Several other brokerages have also recently commented on MRK. Oddo Bhf set a €125.00 ($145.35) target price on Merck KGaA and gave the stock a “buy” rating in a report on Friday, September 29th. Morgan Stanley set a €103.00 ($119.77) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, September 25th. Credit Suisse Group set a €106.00 ($123.26) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) set a €105.00 ($122.09) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Thursday, August 17th. Finally, Kepler Capital Markets set a €119.00 ($138.37) target price on Merck KGaA and gave the stock a “buy” rating in a report on Monday, July 31st. Thirteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of €108.61 ($126.29).
Shares of Merck KGaA (MRK) traded down €1.72 ($2.00) during mid-day trading on Thursday, hitting €89.79 ($104.41). The stock had a trading volume of 952,135 shares. Merck KGaA has a 12 month low of €89.00 ($103.49) and a 12 month high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.